Logo
x

Search category

Subscribe Now

All Posts by Date

Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293

Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293

  • September 21, 2022
Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre

Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinso...

  • September 21, 2022
BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat MoCD Type A

BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat Mo...

  • September 21, 2022
Guerbet’s Elucirem (gadopiclenol) Receives the US FDA’s Approval for Contrast-Enhanced Magnetic Resonance Imaging

Guerbet’s Elucirem (gadopiclenol) Receives the US FDA’s Approval for Contrast-Enhanced Magnetic Resonance Imaging

  • September 21, 2022
argenx Reports the BLA Submission to the US FDA for Efgartigimod to Treat Generalized Myasthenia Gravis

argenx Reports the BLA Submission to the US FDA for Efgartigimod to Treat Generalized Myasthenia Gravis

  • September 21, 2022
CytoReason Expands its 2019 Collaboration with Pfizer for AI Drug Development

CytoReason Expands its 2019 Collaboration with Pfizer for AI Drug Development

  • September 21, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.